Literature DB >> 30408113

Retinal blood flow reduction after panretinal photocoagulation in Type 2 diabetes mellitus: Doppler optical coherence tomography flowmeter pilot study.

Youngseok Song1, Tomofumi Tani1, Tsuneaki Omae1, Akihiro Ishibazawa1, Takafumi Yoshioka1, Kengo Takahashi1, Masahiro Akiba2, Akitoshi Yoshida1.   

Abstract

To use a Doppler optical coherence tomography (DOCT) flowmeter to investigate segmental retinal blood flow (RBF) and sum of the segmental RBFs (SRBF) changes after panretinal photocoagulation (PRP) was used to treat type 2 diabetes mellitus with severe diabetic retinopathy (DR). Data from five patients with proliferative DR (PDR) (mean age 51.9 ± 10.5 years) was analyzed. The vessel diameter (D), average velocity (V), and retinal blood flow (RBF) in veins were measured using a DOCT flowmeter before and four weeks after PRP. Segmental RBF from inferotemporal (IT), superotemporal (ST), inferonasal (IN), and superonasal (SN) veins were measured, and SRBF was defined as the sum of these measurements. All data were analyzed by Wilcoxson test. After PRP, there were statistically significant decreases in the every segmental D, V, RBF (P<0.03) and SRBF (P = 0.002). The other parameters showed no statistically significant differences (P>0.05). The DOCT flowmeter has the potential to be a clinically useful tool to noninvasively evaluate the changes in retinal circulation during PRP in patients with PDR.

Entities:  

Mesh:

Year:  2018        PMID: 30408113      PMCID: PMC6224130          DOI: 10.1371/journal.pone.0207288

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Diabetic retinopathy (DR), a leading cause of blindness in industrialized countries, can be effectively treated using panretinal photocoagulation (PRP), which induces regression of retinal neovascularization (NV) in patients with proliferative diabetic retinopathy (PDR).[1-4] Though the effect of PRP is generally evaluated by assessing reduction from leakage from NV using fluorescein angiography (FA) in clinical practice, FA can have serious complications due to the intravenous injection of fluorescein dye. The incidence rate of a severe reaction was 1:1900, and that of death was 1:222,000.[5] Therefore, developing non-invasive methods to evaluate the effect of PRP is of paramount importance. Several clinical studies in patients with PDR showed reduction of regional retinal blood flow (RBF) and total RBF (TRBF) after PRP using laser Doppler velocimetry (LDV) and photographic measurements of vessel calibers.[6],[7, 8] However, the segmental RBF and TRBF after PRP have not yet been reported in a single study, most likely because acquiring successful RBF measurements with the LDV system requires a highly skilled operator and a substantial amount of time. To replace the LDV system, different techniques have recently been developed based on Doppler optical coherence tomography (DOCT). A study based on the DOCT system showed that there was no significant reduction of TRBF after PRP in patients with poorly controlled type 2 diabetic mellitus (DM).[9] However, the technique used in this study (double circle-based calculation method) measured RBF at only a few moments (< one cardiac cycle), despite the fact that RBF measurements must be measured continuously for at least one cardiac cycle in order to obtain accurate blood velocity in the pulsatile retinal vessels.[9] To overcome these disadvantages, we recently developed a commercially available semi-automated DOCT instrument (Topcon Corp., Tokyo, Japan) with a novel software featuring a segmental scanning method which enables measurements over one cardiac cycle. We confirmed that the DOCT flowmeter enabled accurate and physician-friendly measurement of segmental and sum of the segmental RBFs (SRBF) without any specific skills.[10, 11] The goal of this study was to investigate the changes in segmental RBF and SRBF during PRP in poorly controlled PDR patients using the DOCT flowmeter.

Methods

Design

All methods and experimental protocols were carried out in accordance with the guidelines approved by the institutional review board of the Asahikawa Medical University (Asahikawa Medical University Independent Ethics Committee: AMUIEC) and the tenets of the Declaration of Helsinki. The specific protocols of the study were approved by AMUIEC (the approved number of the study was 17114). All subjects provided written informed consent to participate in this research after receiving a complete explanation of the study design and protocol. 10 patients with DR (male : female = 4 : 6 ) were recruited for the study at Asahikawa Medical University, Asahikawa, Japan. All subjects underwent an ophthalmologic examination, including review of medical history, slit-lamp biomicroscopy, intraocular pressure (IOP) measurement, and funduscopic examination using a 90-diopter lens. The mean arterial blood pressure (MABP) was calculated by the formula ([2 × diastolic BP] + systolic BP)/3. The ocular perfusion pressure (OPP) was calculated by the formula 2/3MABP—IOP.

Inclusion criteria and diagnosis of PDR

Using the Early Treatment of Diabetic Retinopathy Study criteria, cases with type 2 DM including an ETDR score of more than level 61 that were classified as having PDR without any history of prior PRP and/or a history of eye surgery were recruited.[12, 13] Cases with vitreous hemorrhage during the course of the study were excluded to ensure that the scans were successfully obtained. The baseline RBF measurements were taken immediately before PRP. A certified ophthalmic specialist (TO) diagnosed DR in all patients using FA and fundus photographs, and another specialist (AI) applied PRP. These clinicians were masked to the DOCT flowmeter results.

DOCT flowmeter

The retinal vein blood circulation was measured using the DOCT flowmeter.[10] As described in detaile previously, our system is based on a commercially available spectral-domain OCT system (3D OCT-2000 FA, Topcon Corp.) operated at an 800-nm wavelength range.[10] The image-capturing software was modified for Doppler imaging, and the image-processing software was newly developed to measure the RBF according to a previously described segmental scanning method.[10] A total of 180 datasets were captured for approximately 2 seconds with a scan length of 1mm. Multiple vessels were automatically detected, and only veins with a diameter of more than 80 μm were measured.[10] It is generally accepted that the measurement accuracy of velocity is decreased when the Doppler angle is close to 90 degrees, i.e., when the optical axis and flow vector are set to nearly perpendicular.[10] In such cases, the amount of Doppler shift or phase difference becomes equal to 0.[14] The measured flow rates in the arteries and veins seemed to be stable under 85 degrees, however, it was overestimated when the Doppler angle exceeded 86 degrees.[10] Therefore, we excluded the measurement results when the Doppler angle was calculated to be more than 86 degrees.

Imaging procedure and analysis

Retinal blood flow was measured according to a previously described method.[10, 11] As shown in Fig 1, Before BF imaging, a single color fundus image centered at optic disc was captured then region of interest of retinal vessel which is typically one disc diameter away from center of the optic disc was manually chosen. Scan location was also set in this procedure to make sure that it is almost perpendicular to the blood vessel. Flow velocity was calculated using the Doppler angle which is the angle between the incident bean and flow direction, and the amount of Doppler shift (phase image). To calculate the Doppler angle, a pair of scans was implemented before main BF measurement. Detailed description was found in previous literature.[10, 11] In brief, two scans were parallel each other but perpendicular to the blood vessel with Y = 100um apart. By using the phase image, Doppler angle was calculated by identifying the vessel center. For a small segment, the blood vessel can be treated as a straight line. Then, the measurement of cardiac cycle is performed for ~2 seconds. During this scan, scan location is adjusted accordingly by using retinal motion tracking function. During this ~2 seconds measurement, one can see at least one cardiac cycle pulsation curve for most of the cases. Doppler shift image (phase image) was calculated by taking the phase difference between adjacent scans as described previously.[10, 11] Collected phase images were registered and summed to find the vessel location, its center, and diameter by automated software. Flow is then calculated using vessel diameter and velocity.
Fig 1

Image procedure and analysis of measuring retinal blood flow using Doppler optical coherence tomography flow meter (DOCT flowmeter).

A single color fundus image centered at optic disc was captured then region of interest of retinal vessel which is typically one disc diameter away from center of the optic disc was manually chosen. Scan location was set in this procedure to make sure that it is almost perpendicular to the blood vessel. Flow velocity was calculated using the Doppler angle which is the angle between the incident beam and flow direction, and the amount of Doppler shift (phase image). A pair of scans was implemented before main BF measurement to calculate the Doppler angle. Two scans were parallel each other but perpendicular to the blood vessel with Y = 100um apart. By using the phase image, Doppler angle was calculated by identifying the vessel center. The measurement of cardiac cycle is performed for ~2 seconds. During this ~2 seconds measurement, one can see at least one cardiac cycle pulsation curve. Doppler shift image (phase image) was calculated by taking the phase difference between adjacent scans. Collected phase images were registered and summed to find the vessel location, its center, and diameter by automated software. Flow is then calculated using vessel diameter and velocity.

PRP procedure

We began to apply PRP approximately two to three disc diameters away from the center of the macula and peripherally to the equator, i.e., 1,000 to 1,200 spots, 0.1 to 0.2 seconds, and 200- to 400-micron argon laser burns at four sites in the following order: inferiorly, temporally, nasally, and superiorly. PRP was applied during multiple sessions 2 weeks apart (about 400 spots/session) starting from the inferior fundus location. The DOCT flowmeter measurements were performed 4 weeks after the last treatment session. Fluorescein fundus angiography was also performed 1 month following PRP.

Study protocol

An examiner (TT) performed all measurements. After the pupils were dilated with a 0.5% tropicamide eye drop (Santen Pharmaceutical Co., Osaka, Japan), the subjects were required to rest for at least 5 minutes while sitting in a quiet, dimly lit room at a temperature of 25˚C, after which their BP was measured in the left arm. The DOCT flowmeter was assessed after the BP and IOP measurements. The subjects abstained from coffee for at least 24 hours before the measurements. Considering the measuring limit of vessel diameter using DOCT flowmeter (>50μm), the relatively large veins (diameter of 80 μm or more) chosen for measurement had relatively straight segments one disc diameter away from the optic disc. When there were two or more veins in a sector, the biggest one was chosen for the measurement because smaller veins were more likely to give unsuccessful measurements because veins get smaller after PRP. We measured the D, V, and RBF of the inferotemporal (IT), superotemporal (ST), inferonasal (IN), and superonasal (SN) veins (Fig 2), and we defined the SRBF as the sum of all measured veins (IT + ST + IN + SN), and vessel D as the automatically calculated flow image of the horizontal lumen. The waveforms of the veins in the case were shown in Fig 2.
Fig 2

Examples of the site of venous measurements before (baseline) and after panretinal photocoagulation (Post PRP) and the waveforms of the blood velocity for the veins in before and after PRP eyes.

The green bars indicate the inferotemporal (IT) vein, superotemporal (ST) vein, inferonasal (IN) vein, and superonasal (SN) vein. Each waveform of the veins were acquired by Doppler OCT flowmeter. The vertical lines indicate the retinal blood velocity (mm/sec) and the horizontal lines indicate time (sec). Before PRP, before starting PRP; After PRP, four weeks after completing PRP.

Examples of the site of venous measurements before (baseline) and after panretinal photocoagulation (Post PRP) and the waveforms of the blood velocity for the veins in before and after PRP eyes.

The green bars indicate the inferotemporal (IT) vein, superotemporal (ST) vein, inferonasal (IN) vein, and superonasal (SN) vein. Each waveform of the veins were acquired by Doppler OCT flowmeter. The vertical lines indicate the retinal blood velocity (mm/sec) and the horizontal lines indicate time (sec). Before PRP, before starting PRP; After PRP, four weeks after completing PRP.

Statistical analysis

The data were analyzing using Prism 6.0 (GraphPad Software, Inc.). All data were expressed as the mean ± standard deviation. The data were analyzed using Wilcoxon test to compare the measurements before and after PRP. P<0.05 was considered statistically significant.

Results

The demographics of the subjects are shown in Table 1. The mean age of the five subjects was 51.9 ± 10.5 years. The average time from the onset of DM was 11.0 ± 2.9 years (range, 8–16 years). The average hemoglobin A1c (HbA1c) was 9.3 ± 2.0%. All subjects had systemic hypertension and type 2 diabetes. Before PRP therapy, seven subjects (70%) out of 10 had severe non-perfusion area (NPA), two (20%) had pure neovascularization elsewhere (NVE) confirmed by FA (Subjects 1 and 3), one (10%) had both NVE and neovascularization of the disc (NVD) (Subject 2), and none had neovascularization of the iris (NVI). The average number of laser spots applied was 1,217.6 ± 77.0. 8 weeks after PRP the HbA1c, IOP, systemic BP, diastolic BP, MABP, OPP, and heart rate values were similar to before PRP (P = 0.36, 0.36, 0.31, 0.89, 0.39, 0.57, and 0.14, respectively).
Table 1

Patient demographics before panretinal photocoagulation (at baseline).

SubjectAgeGenderDurationLog MARHbA1cHTIOPsBPdBPMean BPOPPPRP Spots
145M10-0.089Yes141416892481142
250F15-0.0811.2Yes141377394491241
334M90.1512.7Yes2115487109521362
467M1206.8Yes1814598114581132
545M8010.9Yes1614877104531256
656F130.16.8Yes161397294471211
749F8010.9Yes1515180104541131
867F1108.5Yes141447195501156
946F80.17.8Yes171387596471278
1060.0F16-0.38.5Yes1914981104501267

Data are expressed as the mean ± standard deviation (SD) of the mean. DM, diabetes mellitus; Duration, duration of DM (years); logMAR, logarithm of the minimum angle of resolution visual acuity; HbA1c, hemoglobin A1c (%); IOP, intraocular pressure; sBP, systolic blood pressure (mmHg); dBP, diastolic blood pressure (mmHg); Mean BP, mean blood pressure (mmHg); HT, hypertension; OPP, ocular perfusion pressure (mmHg); HR, heart rate (bpm); PRP, panretinal photocoagulation; PRP spots, total number of PRP spots.

Data are expressed as the mean ± standard deviation (SD) of the mean. DM, diabetes mellitus; Duration, duration of DM (years); logMAR, logarithm of the minimum angle of resolution visual acuity; HbA1c, hemoglobin A1c (%); IOP, intraocular pressure; sBP, systolic blood pressure (mmHg); dBP, diastolic blood pressure (mmHg); Mean BP, mean blood pressure (mmHg); HT, hypertension; OPP, ocular perfusion pressure (mmHg); HR, heart rate (bpm); PRP, panretinal photocoagulation; PRP spots, total number of PRP spots. The average D, V, and RBF of all segmental vessels are shown in Table 2. The D, V and RBF of all segments decreased significantly after PRP (P < 0.03). SRBF in all subjects also decreased significantly (P = 0.002) (Fig 3).
Table 2

Flow parameter changes before and after panretinal photocoagulation in all segmental vessels.

Diameter, μmVelocity, mm/sRBF, μL/min
Segmental SiteBefore PRPAfter PRPBefore PRPAfter PRPBefore PRPAfter PRP
IT164.6 ± 22.1139.2 ± 17.1*12.2 ± 2.87.7 ± 2.0*14.7 ± 3.96.6 ± 1.8*
ST161.6 ± 19.3129.0 ± 23.8*11.8 ± 4.47.3 ± 4.0*16.0 ± 11.16.8 ± 5.4*
IN131.1 ± 19.6107.0 ± 17.1*11.5 ± 3.26.1 ± 2.7*18.5 ± 3.33.7 ± 1.6*
SN112.0 ± 12.7100.3 ± 10.8*11.2 ± 3.86.5 ± 3.3*17.0 ± 3.83.6 ± 2.5*

Data are expressed as the mean ± standard deviation (SD) of the mean.

*P< 0.05 was considered statistically significant in the comparisons of measurements before and after PRP using Wilcoxon test. PRP, panretinal photocoagulation; RBF, retinal blood flow; IT, inferotemporal vein; ST, superotemporal vein; IN, inferonasal vein; SN, superonasal vein. NVE; neovascularization elsewhere, NVD; neovascularization of the disc, NV; neovascularization.

Fig 3

Sum of the retinal blood flows (SRBF) before and after panretinal photocoagulation (PRP).

SRBF decreased significantly after PRP (P = 0.002, Wilcoxon test). In FA after PRP, though two subjects with NVE and/or NVD (Subjects 1 and 2: yellow lines) had regression of NV, one subject (Subject 3: red line) with NVE did not have regression of NVE. No subject had the formation of new NV. Before PRP, SRBF before starting PRP; After PRP, SRBF four weeks after completing PRP.

Sum of the retinal blood flows (SRBF) before and after panretinal photocoagulation (PRP).

SRBF decreased significantly after PRP (P = 0.002, Wilcoxon test). In FA after PRP, though two subjects with NVE and/or NVD (Subjects 1 and 2: yellow lines) had regression of NV, one subject (Subject 3: red line) with NVE did not have regression of NVE. No subject had the formation of new NV. Before PRP, SRBF before starting PRP; After PRP, SRBF four weeks after completing PRP. Data are expressed as the mean ± standard deviation (SD) of the mean. *P< 0.05 was considered statistically significant in the comparisons of measurements before and after PRP using Wilcoxon test. PRP, panretinal photocoagulation; RBF, retinal blood flow; IT, inferotemporal vein; ST, superotemporal vein; IN, inferonasal vein; SN, superonasal vein. NVE; neovascularization elsewhere, NVD; neovascularization of the disc, NV; neovascularization.

Discussion

In the current study, we evaluated the effect of PRP in both the segmental RBF and SRBF using the semi-automated DOCT flowmeter that we developed. The current findings showed that the segmental RBF and TRBF significantly decreased after PRP (Table 2 and Fig 3). These findings are consistent with the results of previous clinical reports using a laser Doppler technique.[6-8] To the best of our knowledge the current report shows the changes in all segmental RBF (IT, ST, IN, and SN veins) and SRBF after PRP in a single report for the first time. Though an advantage of the laser Doppler method is the ability to measure absolute blood velocity and RBF, measuring RBF with this technique requires a skilled operator and takes a long time. To overcome these issues, several flow meters equipped with the various DOCT methods have been developed.[14, 15] Using our DOCT flowmeter, we not only successfully measured segmental RBF quickly, but also obtained SRBF in patients with poorly controlled DM who needed PRP. Doppler angle detection is an important factor for measuring RBF with the DOCT technique. However, the bidirectional two-beam technique is a reliable method that does not require measurement of the Doppler angle.[14] Although the two-beam technique is suitable for Doppler angle detection if the vessel is nearly parallel to the fundus, the technique requires complex optical settings that use two-beam and two-spectrometer configurations with polarization optics. In contrast, our single-beam–based segmental-scanning DOCT[10] was incorporated into a commercially available spectral-domain OCT system with modified software.[10] In addition, the technical strength of our DOCT flowmeter was the use of fully automated grading and calculation techniques for the RBF measurements in the retinal vessels. One of the reasons why the RBF decreased after PRP could be the alteration of oxygen tension in the retina. Local increases in retinal oxygen tension are thought to occur as the result of laser photocoagulation because PRP destroys the high oxygen-consuming photoreceptors in the outer retina, and PRP induces regression of retinal neovascularization in patients with severe NPA and PDR.[16-18] Elevated oxygen tension in the inner retina induces a retinal vasoconstrictive response.[19-21] Therefore, the current RBF reduction is a reasonable response for both vasoconstrictive reactions, possibly due to the increased retinal tissue oxygen tension following the reaction of the decreased metabolic demand of the retinal tissue after PRP. In the study, there were three subjects with NV (Subjects 1, 2 and 3). The two subjects (subject 1 and 3) out of three had regression of NV after PRP and their SRBF reduced more than 45% after PRP. On the other hand, one subject (subject 2) with active NV even after PRP had only 30% of reduction in SRBF possibly due to the less effective PRP, suggesting that DOCT flowmeter might be able to assess the efficacy of PRP with the rate of RBF reduction after PRP. However, the population of the current study is relatively small and there were only three subjects with NV in the study. Further studies with larger cohort of PDR with NV would confirm the hypothesis. The RBF has an autoregulation system in which the tissue can maintain relatively constant blood flow despite some variations in the OPP,[22] and it is known that autoregulation of the RBF might be impaired in type 1 DM.[23] Though it is possible that decreased OPP may result in decreased RBF, we confirmed that there was no significant change (P = 0.68) in OPP between before and after PRP (Table 1). The current study has some limitations. First, we had a relatively small number of patients in this study. Though the current study revealed useful information that is helpful in understanding the changes in RBF after PRP in patients with DR, further studies with a larger cohort are warranted. Second, we performed follow-up RBF measurements after PRP, however, the current study did not clarify the direct relationship between RBF reduction and the improvement of DR, such as regression of NV on FA images. Further studies are needed to assess the direct relationship between RBF reduction and the improvements of DR after PRP. Third, although we measured HbA1c we did not measure the serum glucose levels before and after PRP, which affected the changes in RBF and endothelial dysfunction in our in vivo study using LDV.[24] Therefore, the current study did not exclude the potential effects of serum glucose level on RBF changes. In addition, there were several veins which were not measured in the study because DOCT flowmeter has the limitation of vessel size to measure, i.e., DOCT flowmeter can measure vessels with more than 50 μm. Improving the resolution of measurements using DOCT flowmeter is expected. In conclusion, our DOCT flowmeter showed that the segmental RBFs and the SRBF decreased 4 weeks after PRP in PDR subjects with poorly controlled type 2 DM. The DOCT flowmeter might be a useful method to noninvasively evaluate the effects of PRP in patients with PDR.
  24 in total

1.  Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1976-04       Impact factor: 5.258

2.  Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

3.  Endothelin-1 contributes to hyperoxia-induced vasoconstriction in the human retina.

Authors:  S Dallinger; G T Dorner; R Wenzel; U Graselli; O Findl; H G Eichler; M Wolzt; L Schmetterer
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-03       Impact factor: 4.799

Review 4.  Fluorescein angiography complication survey.

Authors:  L A Yannuzzi; K T Rohrer; L J Tindel; R S Sobel; M A Costanza; W Shields; E Zang
Journal:  Ophthalmology       Date:  1986-05       Impact factor: 12.079

5.  Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1981-07       Impact factor: 12.079

6.  Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings.

Authors: 
Journal:  Ophthalmology       Date:  1978-01       Impact factor: 12.079

7.  The effect of regional retinal photocoagulation on vitreal oxygen tension.

Authors:  V A Alder; S J Cringle; M Brown
Journal:  Invest Ophthalmol Vis Sci       Date:  1987-07       Impact factor: 4.799

8.  Regulation of human retinal blood flow by endothelin-1.

Authors:  Kaija Polak; Alexandra Luksch; Barbara Frank; Kerstin Jandrasits; Elzbieta Polska; Leopold Schmetterer
Journal:  Exp Eye Res       Date:  2003-05       Impact factor: 3.467

9.  Acute hyperglycemia-induced endothelial dysfunction in retinal arterioles in cats.

Authors:  Kenji Sogawa; Taiji Nagaoka; Naohiro Izumi; Seigo Nakabayashi; Akitoshi Yoshida
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-30       Impact factor: 4.799

10.  Glial Endothelin-1 Regulates Retinal Blood Flow During Hyperoxia in Cats.

Authors:  Youngseok Song; Taiji Nagaoka; Takafumi Yoshioka; Shinji Ono; Takanari Wada; Seigo Nakabayashi; Tomofumi Tani; Akitoshi Yoshida
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-09-01       Impact factor: 4.799

View more
  8 in total

1.  Retinal Nonperfusion in Proliferative Diabetic Retinopathy Before and After Panretinal Photocoagulation Assessed by Widefield OCT Angiography.

Authors:  Jonathan F Russell; Hasenin Al-Khersan; Yingying Shi; Nathan L Scott; John W Hinkle; Kenneth C Fan; Cancan Lyu; William J Feuer; Giovanni Gregori; Philip J Rosenfeld
Journal:  Am J Ophthalmol       Date:  2020-03-13       Impact factor: 5.258

2.  Blood flow rate estimation in optic disc capillaries and vessels using Doppler optical coherence tomography with 3D fast phase unwrapping.

Authors:  Ewelina Pijewska; Marcin Sylwestrzak; Iwona Gorczynska; Szymon Tamborski; Mikolaj A Pawlak; Maciej Szkulmowski
Journal:  Biomed Opt Express       Date:  2020-02-12       Impact factor: 3.732

3.  Changes in choroidal vascular parameters following pan-retinal photocoagulation using swept-source optical coherence tomography.

Authors:  Jee Taek Kim; Nari Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-03       Impact factor: 3.117

4.  Alterations in choroidal vascular parameters following panretinal photocoagulation using enhanced-depth imaging optical coherence tomography in diabetic retinopathy.

Authors:  Ahmad Mirshahi; Kaveh Fadakar; Reza Mirshahi; Elias Khalili Pour; Nazanin Ebrahimiadib; Fariba Ghassemi; Hassan Khojasteh; Fatemeh Bazvand; Sepideh Ghods; Hamid Riazi-Esfahani; Hooshang Faghihi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-09-01       Impact factor: 3.117

5.  Effect of panretinal photocoagulation on optic nerve head blood flow with OCT angiography in patients with diabetic retinopathy.

Authors:  Saher Akbar Amanat; Asad Aslam Khan; Haroon Tayyab; Sohail Sarwar
Journal:  Pak J Med Sci       Date:  2020 Jul-Aug       Impact factor: 1.088

6.  Retinal Arteriole Pulse Waveform Analysis Using a Fully-Automated Doppler Optical Coherence Tomography Flowmeter: a Pilot Study.

Authors:  Jun Sakai; Kana J Minamide; Syunsuke Nakamura; Young-Seok Song; Tomofumi Tani; Akitoshi Yoshida; Masahiro Akiba
Journal:  Transl Vis Sci Technol       Date:  2019-05-06       Impact factor: 3.283

7.  Effect of insulin treatment on pulsatility ratio and resistance index of the retinal artery in patients with type 2 diabetes.

Authors:  Tsuneaki Omae; Youngseok Song; Takafumi Yoshioka; Tomofumi Tani; Akitoshi Yoshida
Journal:  PLoS One       Date:  2021-07-20       Impact factor: 3.240

8.  Deterioration of Retinal Blood Flow Parameters in Branch Retinal Vein Occlusion Measured by Doppler Optical Coherence Tomography Flowmeter.

Authors:  Kengo Takahashi; Youngseok Song; Kenji Sogawa; Takafumi Yoshioka; Tomofumi Tani; Satoshi Ishiko; Akitoshi Yoshida
Journal:  J Clin Med       Date:  2020-06-13       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.